{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:58:21Z","timestamp":1781143101894,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004420","name":"Wakayama Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004420","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109454","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:11:27Z","timestamp":1778627487000},"page":"109454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN)"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6757-3491","authenticated-orcid":false,"given":"Yuhei","family":"Harutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-5512","authenticated-orcid":false,"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-6896","authenticated-orcid":false,"given":"Eri","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Shibaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Nakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-8532","authenticated-orcid":false,"given":"Koichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-3488","authenticated-orcid":false,"given":"Yuichi","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Washioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuninobu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1563-7181","authenticated-orcid":false,"given":"Ke","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0853","authenticated-orcid":false,"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109454_b0005","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non\u2013Small Cell Lung Cancer, Version 7.2025. J. Natl. Compr. Canc. Netw. 23 (2025) 354\u2013362. doi: 10.6004\/jnccn.2025.0043.","DOI":"10.6004\/jnccn.2025.0043"},{"key":"10.1016\/j.lungcan.2026.109454_b0010","first-page":"e45","article-title":"Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1","volume":"43","author":"Owen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109454_b0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109454_b0020","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u226550","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109454_b0025","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109454_b0030","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109454_b0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109454_b0040","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.3390\/cancers14122970","article-title":"Is the efficacy of adding ramucirumab to docetaxel related to a history of immune checkpoint inhibitors in real-world clinical practice?","volume":"14","author":"Nishimura","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109454_b0045","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.21873\/anticanres.13688","article-title":"Previous immune checkpoint inhibitor treatment increases the efficacy of docetaxel and ramucirumab combination chemotherapy","volume":"39","author":"Harada","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2026.109454_b0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.21037\/tlcr.2019.08.07","article-title":"Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients","volume":"8","author":"Yoshimura","year":"2019","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109454_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000350","article-title":"Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)","volume":"8","author":"Kato","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109454_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102303","article-title":"Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial","volume":"66","author":"Matsuzawa","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lungcan.2026.109454_b0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","article-title":"A randomized, double-blind, phase II study of ramucirumab plus docetaxel versus placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy","volume":"99","author":"Yoh","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109454_b0070","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JTO.0b013e318260e106","article-title":"Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab","volume":"7","author":"Hoang","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109454_b0075","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdp392","article-title":"Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer","volume":"21","author":"Syrigos","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109454_b0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2023.01.025","article-title":"Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)","volume":"184","author":"Nakamura","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109454_b0085","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2026.109454_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000974","article-title":"Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma","volume":"8","author":"Thompson","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109454_b0095","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.3390\/cancers12113374","article-title":"Tumor MHC Expression Guides First-Line Immunotherapy selection in Melanoma","volume":"12","author":"Shklovskaya","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109454_b0100","doi-asserted-by":"crossref","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 362(2018) eaar3593. doi: 10.1126\/science.aar3593. Erratum in: Science. 363 (2019) eaax1384. doi: 10.1126\/science.aax1384.","DOI":"10.1126\/science.aax1384"},{"key":"10.1016\/j.lungcan.2026.109454_b0105","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41564-024-01695-w","article-title":"Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice","volume":"9","author":"Liu","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.lungcan.2026.109454_b0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2026.109454_b0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2026.109454_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100068","article-title":"Role of chemotherapeutic drugs in immunomodulation of cancer","volume":"4","author":"Mukherjee","year":"2023","journal-title":"Curr. Res. Immunol."},{"key":"10.1016\/j.lungcan.2026.109454_b0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-018-0403-1","article-title":"Targeting VEGFR2 with Ramucirumab strongly impacts effector\/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment","volume":"6","author":"Tada","year":"2018","journal-title":"J. Immunother. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:14:21Z","timestamp":1781140461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"alternative-id":["S0169500226005155"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109454","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109454"}}